A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol
-
Published:2024-09
Issue:5
Volume:62
Page:897-900
-
ISSN:2212-5345
-
Container-title:Respiratory Investigation
-
language:en
-
Short-container-title:Respiratory Investigation
Author:
Nakamura NaokiORCID,
Makimoto GoORCID,
Tanaka Takaaki,
Kato Yuka,
Oze IsaoORCID,
Kozuki Toshiyuki,
Yokoyama ToshihideORCID,
Ichikawa Hirohisa,
Kuyama Shoichi,
Hara NaofumiORCID,
Maeda Yoshinobu,
Hotta KatsuyukiORCID
Reference9 articles.
1. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer;Satouchi;Lung Cancer,2013
2. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update;Loprinzi;J Clin Oncol,2020
3. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial;Smith;JAMA,2013
4. The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy;Tawata;Diabetes Res Clin Pract,1994
5. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study;Oki;Int J Clin Oncol,2015